A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)

被引：2

作者：

Christofyllakis, Konstantinos ^{[1
]}

Poeschel, Viola ^{[1
]}

Altmann, Bettina ^{[2
]}

Maurer, Stephanie ^{[1
]}

Lesan, Vadim ^{[1
]}

Bittenbring, Joerg ^{[1
]}

Kos, Igor Age ^{[1
]}

Kaddu-Mulindwa, Dominic ^{[1
]}

Abdi, Zanir ^{[1
]}

Fleser, Octavian ^{[1
]}

Altmeyer, Sarah ^{[1
]}

Neuendorff, Nina Rosa ^{[3
]}

Nickelsen, Maike ^{[4
]}

Held, Gerhard ^{[5
]}

Dreyling, Martin ^{[6
]}

Zettl, Florian ^{[7
]}

Buske, Christian ^{[8
]}

Lenz, Georg ^{[9
]}

Glass, Bertram ^{[10
]}

Chapuy, Bjoern ^{[11
]}

Schmitz, Norbert ^{[9
]}

Vassilakopoulos, Theodoros ^{[12
]}

Ott, German ^{[13
,14
]}

Siebert, Reiner ^{[15
,16
]}

Viardot, Andreas ^{[15
,16
]}

Scherer, Florian ^{[17
]}

Schmitz, Roland ^{[18
]}

Rosenwald, Andreas ^{[19
]}

Hellwig, Dirk ^{[20
]}

Loeffler, Markus ^{[2
]}

Stilgenbauer, Stephan ^{[21
]}

Thurner, Lorenz ^{[1
]}

Bewarder, Moritz ^{[1
]}

Ziepert, Marita ^{[2
]}

机构：

[1] Saarland Univ, Med Ctr, Dept Internal Med Oncol Hematol Clin Immunol & Rh, Homburg, Germany

[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany

[3] Univ Hosp Essen, Dept Haematol & Stem Cell Transplantat, Essen, Germany

[4] Onkol Lerchenfeld, Hamburg, Germany

[5] Westpfalz Klinikum, Dept Internal Med 1, Kaiserslautern, Germany

[6] LMU Univ Hosp, Dept Internal Med 3, Munich, Germany

[7] Klinikum Traunstein, Dept Hematol & Oncol, Traunstein, Germany

[8] Univ Hosp Ulm, Inst Expt Canc Res, Ulm, Germany

[9] Univ Hosp Muenster, Dept Med A Hematol Oncol & Pneumol, Munster, Germany

[10] Asklepios Klin St Georg, Dept Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[11] Charite, Med Ctr Berlin, Dept Hematol Oncol & Tumor Immunol, Campus Benjamin Franklin, Berlin, Germany

[12] Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece

[13] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany

[14] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[15] Ulm Univ, Inst Human Genet, Ulm, Germany

[16] Ulm Univ, Med Ctr, Ulm, Germany

[17] Univ Freiburg, Fac Med, Dept Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany

[18] Univ Hosp Giessen, Inst Pathol Mol Cytol & Funct Genom, Giessen, Germany

[19] Julius Maximilians Univ Wurzburg, Inst Pathol, Wurzburg, Germany

[20] Univ Hosp Regensburg, Dept Nucl Med, Regensburg, Germany

[21] Univ Hosp Ulm, Div CLL, Dept Internal Med 3, Ulm, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179200

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[1] Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)
Vitolo, Umberto
Trneny, Marek
Belada, David
Carella, Angelo M.
Chua, Neil
Abrisqueta, Pau
Demeter, Judit
Flinn, Ian W.
Hong, Xiaonan
Kim, Won Seog
Pinto, Antonio
Burke, John M.
Shi, Yuankai
Tatsumi, Yoichi
Oestergaard, Mikkel
Wenger, Michael K.
Fingerle-Rowson, Gunter
Catalani, Olivier
Nielsen, Tina
Martelli, Maurizio
Sehn, Laurie H.
BLOOD, 2016, 128 (22)
[2] A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
Laurie H. Sehn
Maurizio Martelli
Marek Trněný
Wenxin Liu
Christopher R. Bolen
Andrea Knapp
Deniz Sahin
Gila Sellam
Umberto Vitolo
Journal of Hematology & Oncology, 13
[3] Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Sahn, Laurie H.
Martelli, Maurizio
Trneny, Marek
Liu, Wenxin
Bolen, Christopher R.
Knapp, Andrea
Sahin, Deniz
Sellam, Gila
Vitolo, Umberto
BLOOD, 2019, 134
[4] A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
Sehn, Laurie H.
Martelli, Maurizio
Trneny, Marek
Liu, Wenxin
Bolen, Christopher R.
Knapp, Andrea
Sahin, Deniz
Sellam, Gila
Vitolo, Umberto
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[5] Acrue: A Phase 2, Open-Label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma
Perini, Guilherme F.
Graff, Tara
Roos, Jack
Hermann, Richard
Lovenklev, Magnus
Shaw, Bob
Budde, L. Elizabeth
BLOOD, 2023, 142
[6] Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Li, Xueying
Huang, He
Xu, Bing
Guo, Hongqiang
Lin, Yingcheng
Ye, Sheng
Yi, Jiqun
Li, Wenyu
Wu, Xiangyuan
Wang, Wei
Zhang, Hongyu
Xie, Derong
Peng, Jiewen
Cao, Yabing
Pu, Xingxiang
Guo, Chengcheng
Hong, Huangming
Wang, Zhao
Fang, Xiaojie
Zhou, Yong
Lin, Suxia
Liu, Qing
Lin, Tongyu
CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 919 - 932
[7] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Goy, Andre
Ramchandren, Radhakrishnan
Ghosh, Nilanjan
Munoz, Javier
Morgan, David S.
Dang, Nam H.
Knapp, Mark
Delioukina, Maria
Kingsley, Edwin C.
Anh Tran
Ping, Jerry
Beaupre, Darrin M.
Neuenburg, Jutta K.
Ruan, Jia
BLOOD, 2016, 128 (22)
[8] A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
Park, Steven I.
Richards, Kristy L.
Asch, Adam S.
Olajide, Oludamilola
Deal, Allison M.
Ivanova, Anastasia
Wall, James G.
Sobol, Anna L.
Foster, Matthew C.
Muss, Hyman B.
Shea, Thomas C.
BLOOD, 2013, 122 (21)
[9] ACRUE: A Phase 2, Open-Label Study of Acalabrutinib in Combination With Rituximab in Elderly and/or Frail Patients With Treatment-Naive Diffuse Large B- Cell Lymphoma
Perini, Guilherme F.
Graff, Tara
Roos, Jack
Hermann, Richard
Lovenklev, Magnus
Shaw, Bob
Budde, Lihua E.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S462 - S462
[10] A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-Cell Lymphoma (LOTIS-9)
Westin, Jason
Burke, John M.
Chapman, Andrew E.
Kilavuz, Turk
Xu, Cindy
Shmuely, Yochi
Radford, John
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S368 - S368

← 1 2 3 4 5 →